Question explored with the scientific record
Who benefits from mRNA vaccine
The short version: mRNA vaccines clearly reduce severe COVID-19 and death in older adults and people with chronic conditions, but the evidence for healthy young adults is weaker and the long-term safety data is thin.
The strongest evidence comes from a 2026 Norwegian study of 4.6 million adults. People who got three or more mRNA doses had about a 60% lower risk of dying from any cause compared to unvaccinated people, after adjusting for age, sex, and medical risk [1]. The benefit was similar across all age groups. A Danish study of 101,786 heart failure patients found that vaccinated patients had a 0.3% lower absolute risk of death within 90 days compared to a matched unvaccinated group from 2019 [2]. An Israeli study of 43,596 long-term care residents (average age 83) found that the vaccine cut COVID-19 deaths by 85% and all-cause deaths by 64% within 28 days of the first dose [3].
But the picture is not clean. A 2025 US nursing home study of 15,022 facilities found that after a COVID-19 outbreak, fully vaccinated residents had elevated mortality that lasted five weeks, while unvaccinated residents returned to baseline after one week [4]. The authors note this may be because frailer residents were vaccinated first. A 2026 US county-level study of over 3,000 counties found a positive association between higher vaccine uptake and higher excess mortality in 2022 and 2023 [5]. The study cannot prove causation, but it is a signal that deserves investigation. A forensic reanalysis of Pfizer's own trial data found 21 deaths in the vaccine group versus 1 in the placebo group during the first 33 weeks, with a disproportionate number of cardiac deaths in the vaccine arm [6].
| Population | Benefit (all-cause mortality reduction) | Caveat |
|---|---|---|
| General adults (Norway, 3+ doses) | ~60% lower risk [1] | Observational; healthy vaccinee bias possible |
| Heart failure patients (Denmark) | 0.3% absolute risk reduction [2] | Compared to 2019, not concurrent unvaccinated |
| Nursing home residents (Israel) | 64% lower all-cause death [3] | Frail elderly; waning with age |
| Nursing homes (US, 2022-23) | Shorter-lived benefit than expected [4] | Vaccinated had longer elevated mortality after outbreaks |
| US counties (population-level) | Higher vaccine uptake linked to higher excess death [5] | Ecological; cannot prove causation |
My call: mRNA vaccines reduce severe COVID-19 and death in older adults and people with chronic conditions, but the evidence for healthy young adults is weaker, and the long-term safety data is missing. The burden of proof for repeated boosting in low-risk people has not been met. Confidence: moderate for older adults and high-risk groups; low for healthy young adults.
Sources used 6
-
COVID-19 mRNA vaccination and all-cause mortality in the adult population in Norway during 2021–2023: a population-based cohort study
In a Norwegian population-based cohort of 4,645,910 adults followed from January 2021 to December 2023, individuals who received three or more mRNA vaccine doses had a substantially lower adjusted all-cause mortality rate than unvaccinated individuals, with fully vaccinated adul…
DOI: 10.1136/bmjph-2024-001859 -
Risk of worsening heart failure and all-cause mortality following mRNA COVID-19 vaccination in patients with heart failure: a Danish nationwide real-world safety study
In a nationwide Danish cohort of 101,786 patients with heart failure, SARS-CoV-2 mRNA vaccination was associated with a lower 90-day all-cause mortality risk compared with a matched 2019 unvaccinated cohort and with no difference in worsening heart failure, myocarditis, or venou…
DOI: 10.1093/eurheartj/ehac544.881 -
BNT162b2 mRNA COVID-19 (Comirnaty) Vaccine Effectiveness in Elderly Patients Who Live in Long-Term Care Facilities: A Nationwide Cohort
A nationwide Israeli cohort study of long-term care facility residents shows that the BNT162b2 mRNA COVID-19 vaccine substantially reduces SARS-CoV-2 infection, COVID-19–related death, and all-cause mortality within 28 days of vaccination, with waning effectiveness with increasi…
DOI: 10.1159/000521899 -
Temporal patterns of all-cause mortality among U.S. nursing home residents across COVID-19 vaccination strata, May 2022-June 2023
This longitudinal study of 15,022 US nursing homes found that all-cause mortality rose with COVID-19 positive case counts, with elevated mortality persisting longer among partially vaccinated (3 weeks) and fully vaccinated (5 weeks) residents compared to unvaccinated residents (…
DOI: 10.18103/mra.v14i3.7380 -
Why COVID-19 vaccination cannot be ruled out as an explanation for all-cause excess mortality in the pandemic’s aftermath: A population-level study of over 3,000 US counties with over 320 million people
A US county-level study found positive associations between per-capita COVID-19 vaccine uptake and all-cause excess mortality in 2022 and 2023, even when adjusting for lagged mortality, but the design cannot establish causation.
DOI: 10.12688/f1000research.177279.1 -
Forensic analysis of the 38 subject deaths in the 6-Month Interim Report of the Pfizer/BioNTech BNT162b2 mRNA Vaccine Clinical Trial
A forensic reanalysis of Pfizer/BioNTech's Phase 2/3 BNT162b2 trial data (C4591001) focusing on the 38 deaths during the first 33 weeks, reporting a disproportionate number of cardiac-related deaths among vaccine recipients, and alleging delayed/opaque reporting that may have in…
DOI: 10.56098/ijvtpr.v3i1.85